The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]
To join the phase 2 POSTPONE trial investigating pacritinib for advanced prostate cancer, patients must have metastases that are strongly positive for STAT5 activation—specifically, a recent tumor biopsy must show detectable nuclear STAT5 in more than 5% of cancer cells. This trial is built upon robust laboratory and clinical findings showing that the JAK2-STAT5 pathway […]
Pasritamig is a bispecific T-cell engager that targets human kallikrein 2 (KLK2), a protein found primarily in prostate tissue and often retained in advanced prostate cancer. This drug brings T cells into close contact with KLK2-expressing tumor cells, directing immune responses against the cancer. In phase 1 studies, pasritamig was evaluated in men with metastatic […]
In a recent presentation, Dr. Oliver Sartor highlighted Lead-212 (Pb-212) as a promising next step in precision radioligand therapy for metastatic castration-resistant prostate cancer. Developed by the same Oslo-based team that introduced Radium-223, Lead-212 is being studied in the ARTISAN (AB001) trial and represents a significant evolution in alpha-emitting radiopharmaceuticals. Its defining features are a […]
CBPD‑409 is an experimental, oral medicine designed to remove two helper proteins, CBP and p300, that prostate tumors use to turn cancer‑driving genes on. These proteins partner with the androgen receptor (AR), the key signal that fuels most prostate cancers, especially in the advanced, treatment‑resistant setting. By tagging CBP and p300 for destruction, a strategy […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s photo features me and my better half! (Mine is the hand underneath.) We celebrated our anniversary, and here I am, still full from dinner, finishing up the newsletter! This week, too, we have some exciting updates on […]
The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]
AB-3028 represents a next-generation approach to solid-tumor CAR T therapy tailored to the unique challenges of metastatic castration-resistant prostate cancer. CAR T cells, transformative in hematologic malignancies, have struggled in solid tumors due to heterogeneous antigen expression, on-target off-tumor risks, suppressive cytokines like TGF-β, and chronic stimulation that drives exhaustion. AB-3028 was engineered to counter […]
A new study shows, published on Nature, that a little-known protein called PTGES3 helps prostate cancer cells keep using male hormone signals to grow, even when treatments are trying to shut those signals down. Blocking this helper protein cut off the cancer’s fuel supply in lab tests and slowed tumors in mice, pointing to a […]
GenSci143 (aka GenSci-143) is a bispecific antibody-drug conjugate under development for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. The construct targets B7-H3 (CD276) and PSMA simultaneously with a bispecific antibody, coupled via a stable, cleavable linker to a topoisomerase I inhibitor payload, aiming to improve tumor cell killing and bystander effects across heterogeneous […]